17:13 , Jul 20, 2018 |  BC Week In Review  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
10:02 , Jul 18, 2018 |  BC Extra  |  Company News

Revolution, Sanofi partner on SHP-2 inhibitors for cancer

Revolution Medicines Inc. (Redwood City, Calif.) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to co-develop src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitors to treat cancer, including Revolution's lead candidate RMC-4630. Revolution will receive an upfront...
18:21 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer, sarcoma Cell culture studies suggest inhibiting IFT88 or SCLT1 could help treat kinase inhibitor-resistant lung cancer and rhabdomyosarcoma. In a human EGFR inhibitor-resistant non-small cell lung cancer (NSCLC) cell line, the EGFR inhibitor...
16:27 , Jun 12, 2018 |  BioCentury  |  Emerging Company Profile

A Cancer Target Revolution

Revolution Medicines Inc. is developing inhibitors that target non-catalytic sites on proteins to block cell signaling pathways, such as Ras, that drive cancer cell proliferation. The company’s platform combines synthetic and medicinal chemistry, biochemistry, and structural...
23:00 , Jun 7, 2018 |  BC Extra  |  Preclinical News

Targeting tumor cilia could reverse resistance to kinase inhibitors

A Cell Reports study from Institute of Cancer Research (ICR) researchers and colleagues identified cilia on tumor cells as a new, potentially universal target for sensitizing drug-resistant cells to kinase inhibitors. The research suggests inhibiting...
19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
15:05 , Apr 27, 2018 |  BioCentury  |  Finance

Revolution revamp

Revolution Medicines Inc.’s pivot to cancer and preclinical proof-of-concept data for its lead program convinced Nextech Invest to lead the company’s $56 million series B round. Fellow new investors Casdin Capital and Schroder Adveq and existing...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
12:15 , Mar 29, 2018 |  BC Extra  |  Preclinical News

USP15 a potential ovarian cancer target

A study in Nature Communications by researchers at Baylor College of Medicine and University of Texas MD Anderson Cancer Center suggests inhibiting ubiquitin specific peptidase 15 could help treat ovarian cancers that carry the R175H...
20:22 , Mar 15, 2018 |  BC Extra  |  Clinical News

Adapting T cell manufacturing methods could improve CAR Ts

Researchers at The Children's Hospital of Philadelphia identified key factors that affect the potential of T cells from pediatric patients with leukemias, lymphomas and sarcomas to be modified into effective CAR T cell therapies. The...